Biological and biochemical studies of the herpesvirus of chimpanzees previously demonstrated to be antigenically related to human Epstein-Barr virus (EBV) indicated that the agent is similar to EBV in that: (i) leukocyte culture of chimpanzees whose sera contained antibody against EBV capsid antigen could yield long-term lymphoblastoid cell lines (Ch-LCL) with B-cell characteristics;
Epstein-Barr virus (EBV) has been closely associated with Burkitt's lymphoma and nasopharyngeal carcinoma and is the causative agent of classical heterophile-positive acute infectious mononucleosis. Studies of the pathophysiology of EBV infection and of its possible role in malignant transformation have been limited by the narrow host range of the agent. Chimpanzee (17) and marmoset (21) lymphocytes can be infected with EBV. Immunosuppression of EBV-infected marmosets can lead to lymphoma (30) . In general, however, herpesviruses behave differently in heterologous species. It would therefore be of importance to establish whether there is an EBVrelated agent indigenous to non-human primates. This would offer an opportunity to study the pathophysiology of this virus infection in the natural species.
Previous reports have suggested that infection with an agent similar to EBV is prevalent among populations of several non-human primate species. Thus, the sera of chimpanzees and Old World monkeys (3, 5, 10) , as well as the sera of marmosets and prosimians (6) , frequently contain antibody to EBV that can be detected by complement fixation (CF) tests as well as by immunodiffusion and indirect immunofluorescence assays (11, 32) . Long-term lymphoid cell lines can be established from chimpanzee blood (17) . These cell lines have been shown to contain a herpes-type virus (17) and to react with EBV-positive human sera in immunodiffusion and indirect immunofluorescence assays (11, 32) . A line of identity was observed between an antigen detected by immunodiffusion in extracts of a chimpanzee lymphoid cell line and an EBV-infected human lymphoid cell line using EBV-positive human sera, suggesting that chimpanzee cells contain an EBV-related antigen (32) .
Several lines of evidence suggest that nonhuman primates can acquire infection with an EBV-related agent without human contact and that the agent is distinct from human EBV. (i) Fifty percent of rhesus monkeys bled at the time of capture had CF antibody to EBV. Furthermore, two of three wild chimpanzees living without human contact in the Budango Forest in western Uganda had antibody to EBV antigens detectable by indirect immunofluorescence (19) . (ii) Absorption of EBV-reactive chimpanzee sera with EBV-infected human cells resulted in a serum that reacted well with chimpanzee lymphoid cell lines (Ch-LCL) in indirect immunofluorescence but poorly with EBV-infected human cells, suggesting that Ch-LCL contain distinct antigenic activity (11) .
The experiments reported here were undertaken to further characterize the extent of anti-genic and biochemical relatedness of the chimpanzee agent to human EBV. MATERIALS (12) .
The procedures used in the separation of chimpanzee leukocytes from heparinized whole blood and in leukocyte cultivation were those described previously for the separation and cultivation of human leukocytes (8) . The leukocyte cultures were incubated at 37°C in a CO, incubator and maintained by periodic medium changes as long as viable cells were detectable. The emergence of long-term lymphoblastoid cell lines was heralded by the appearance of large floating cells usually in aggregates, increased metabolic activity, and cell growth. The continuous Ch-LCL were designated by the number of the animal of origin and were maintained for periods of 4 to 12 months.
Human lymphoid cell lines. The P3 HR-1 (HR-1) cell line (15) was used for determination of VCA and contained 5 to 10% VCA-positive cells. The Raji cell line (26) was used as a source of EBV-determined soluble CF antigens (24) and EBV-related nuclear antigens (EBNA) (29) , and for induction of EBVassociated early antigens (EA) (7) . The Vax cell line was derived from an ascitic tumor of an American Burkitt's lymphoma patient by Ian T. Magrath. These cells have B-cell marker characteristics and do not contain EBV DNA or EBNA (Magrath, personal communication).
Determination of T-and B-lymphocyte markers. Chimpanzee lymphoblasts were classified by three techniques: formation of sheep cell rosettes (18); determination of complement receptors on the cell surface using sensitized sheep erythrocytes preincubated with antibody and complement (2); and staining the surface immunoglobulin of viable cells with fluorescein-isothiocyanate (FITC)-conjugated horse anti-human immunoglobulin (27) . Rabbit antibody against sheep erythrocytes was purchased from Difco Laboratories, Detroit, Mich. FITC-conjugated horse anti-human immunoglobulin was purchased from Roboz Co., Washington, D.C.
Virus isolation procedures. Two methods were used in an attempt to determine whether Ch-LCL contained an agent that could transform marmoset or human lymphocytes into cells capable of longterm growth in culture.
(i) Cell-free lysates of Ch-LCL prepared by three cycles of freezing and thawing of packed cells, or spent media concentrated 100-fold by centrifugation at 100,000 x g for 1 h, were filtered through 0.45-gm filters (Millipore Corp., Bedford, Mass.). These preparations were inoculated onto cultures of fresh cord blood leukocytes or marmoset leukocytes, which were then maintained and observed for 4 to 6 weeks.
(ii) In co-cultivation experiments, Ch-LCL derived from male animals were lethally irradiated with 5,000 R. Mixtures of 5 x 106 cord blood lymphocytes or 1 x 106 to 2 x 106 marmoset lymphocytes and 0.5 x 106 to 2.5 x 106 lethally irradiated chimpanzee lymphoid cells were centrifuged at 50 x g for 3 min to promote intimate cell contact. The mixed lymphocyte cultures and individual control cultures of cord blood and of marmoset and irradiated chimpanzee lymphocytes were incubated for 4 to 5 weeks at 37°C in 5% CO2 with periodic medium changes.
Detection of other simian viruses such as cytomegalovirus, adenovirus, or foamy virus was performed by inoculation of cultures of rabbit kidney, African green monkey kidney, HeLa, and W138 cells with either cell-free lysates or cells and culture fluid of Ch-LCL.
Serological tests. The procedures used in the preparation of soluble antigens from lymphoblastoid cells and for assay for CF antibody activity have been described in detail previously (4) . EBV-associated antigens were detected by indirect immunofluorescence (12) using iododeoxyuridine (IUdR)-treated Raji cells as the source of EA and HR-1 cells as a source of VCA.
Cytoplasmic fluorescence in Ch-LCL was detected by indirect immunofluorescence using a cell line (Ch 14, 23, or 765) in which 2 to 5% of the cells exhibited cytoplasmic fluorescence. The procedures used in induction of cytoplasmic antigens in chimpanzee lymphoblasts and for detection of the induced antigenic activity by indirect immunofluorescence were identical to those previously used for detection of EA in Raji cells (7) .
FITC-conjugated goat anti-human globulin (Hyland Co., Los Angeles, Calif.) was used in indirect immunofluorescence assays with human and nonhuman primate sera. The EBNA and the intranuclear antigen in chimpanzee cells (Ch-NA) were detected using the three-step anticomplementary immunofluorescence (ACIF) test (13) . The controls for the ACIF test included EBNA-negative Vax cells and EBNA-positive and -negative reference sera. EBV-associated membrane antigens (MA) were detected on the surface of viable cells by indirect immunofluorescence (23) .
Serum antibody absorption experiments were performed with 30 to 40% (vol/vol) cell lysates. A 1:4 dilution of heat-inactivated serum was absorbed at 37°C for 1 h and at 4°C for 8 h. The absorption was carried out twice.
EBV preparations. Leukocyte-transforming virus was derived from the spent culture fluid B95-8 cells (21) . The cell-free supernatant fluid of 5-to 6-day cultures was passed through 0.45-,um filter, and aliquots were stored at -70°C. These preparations contained 104 to 105 transforming units/0.25 ml as tested with human cord blood leukocytes (9) . Nontransforming EBV was derived from HR-1 cultures kindly provided by the Research and Logistics Branch of the Special Virus Cancer Program of the National Cancer Institute. Cell-free supernatants were pelleted at 100,000 x g for 1 h, and the virus-VOL. 19, 1976 on October 18, 2017 by guest http://jvi.asm.org/ Downloaded from containing pellets were resuspended in 1/200 volume of the original volume. These preparations when titrated on Raji cells for their ability to induce EBV EA (14) had a titer of 10:' to 10:''/0. 25 Preparation of labeled viral D)NA. EBV was purified from extracellular fluid of HR-1 cells as previously described (25) . DNA was prepared from purified EBV and labeled in vitro with 'Hithymidine triphosphate (specific activity, 50 Ci/mmol; New England Nuclear Corp., Boston, Mass.) using Escherichia coli DNA polymerase 1 (Boehringer Corp., New York, N.Y.) (25) . The specific activity of the resultant DNA (IHIEBV HR-1 DNA) was approximately 3 x 1i0 cpm/,ug. Relationship between EBV-associated antigens and the antigens of Ch-LCL. The extent of antigenic cross-reactivity of EBV and the EBV-related agent in CH-LCL was investigated by (i) comparing the reactivity of selected human sera, VCA+ EBNA+, VCA+ EBNA-, VCA+ EA+, VCA+ EA-, or VCA-EA-EBNA-, with antigens present in EBV-infected human and Ch-LCL and in spontaneously performed lymphoblastoid cells; and by (ii) comparing the reactivity of non-human primate sera with antigens present in Ch-LCL and EBV-infected human and chimpanzee lymphoblastoid cells. Nuclear, cytoplasmic, IUdR-induced cytoplasmic, membrane, and neutralizing antigens of these cell lines were compared. The results were as follows.
(i) Intranuclear antigens detectable by ACIF. One hundred and six human and nonhuman primate sera were assayed for antibody to EBV VCA and for activity against EBNA or Ch-NA in ACIF tests ( Table 2 ). None of the sera reacted with the EBV genome-negative Vax cells and were all therefore considered to be free of nonspecific antinuclear antibodies. The sera of 30 humans and 4 orangutans were negative for VCA and failed to react in the ACIF test with Raji or chimpanzee cells. The 39 human sera with antibody to VCA were positive in ACIF tests against EBNA and nuclear antigens of EBV-transformed Ch 784 cells. Seven of these 39 VCA antibody-positive human sera also reacted with Ch-NA of spontaneously transformed chimpanzee cells in ACIF.
By contrast, none of 20 chimpanzee sera with VCA antibodies detected EBNA in Raji or EBV-transformed Ch 784 cells, but 55% (11/20) reacted strongly with Ch-NA in spontaneously transformed Ch 888 cells. Figure 1 illustrates ACIF staining of Ch-NA in Ch 888 cells. Generally 90 to 95% of the cells were positive, and a similar staining pattern was observed with the other spontaneously transformed Ch-LCL.
A comparison of CF and ACIF reactivity of VCA antibody-positive human and chimpanzee sera (Table 3) (ii) Induced cytoplasmic antigens. Treatment of Raji cells with halogenated pyrimidines has been previously shown to induce the synthesis of EA (7). Twelve of the 39 VCA+ human sera had antibody to EA (Table 5 ). All 12 VCA+ EA+ human sera reacted with cytoplasmic antigens induced by IUdR in 1 to 2% of Ch 888 and 889 cells. None of the VCA+ EAhuman sera reacted with the induced antigens in chimpanzee cells. Similarly, of 20 VCA+ chimpanzee sera, 8 reacted with IUdR-induced antigens in Ch-LCL and had EA antibodies, whereas 12 EA-chimpanzee sera failed to react with IUdR-induced antigens in chimpanzee cells.
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b Reciprocal of ACIF titer. EBNA. Although the intranuclear antigen of the Ch-LCL has some reactivity with human EBNA+ sera, some human sera with high anti-EBNA titer do not contain activity against Ch-NA. The failure of Ch-LCL to contain major components of EBNA and the presence in these cells of a new nuclear antigen cannot be attributed to a difference in expression of EBV in human and non-human primate lymphocytes, since chimpanzee lymphocytes infected with EBV contain a nuclear antigen identifiable as EBNA by its reactivity with all EBNA-positive human sera (many of which lack activity against Ch-NA) and by its lack of reactivity with Ch-NA-positive chimpanzee sera. (ii) The DNA-DNA hybridization data suggested that spontaneously transformed Ch-LCL do not contain all the sequences of EBV. Because of the small number of copies of EBV-homologous DNA in spontaneously transformed Ch-LCL, we cannot precisely determine the point at which hybridization of Ch-LCL DNA with EBV DNA reaches a plateau. However, the fact that the hybridization with EBV DNA reaches a plateau at approximately 35 to 45% hybridization is unlikely to be due to an artifact in that hybridizations of labeled EBV DNA with unlabeled DNA containing even fewer copies of EBV DNA than are present in Ch-LCL proceeds at a slower initial rate, but does not reach a plateau (Fig. 2) . Quantitation and precise determination of which sequences are missing from Ch-LCL will require hybridization with specific sequences of EBV DNA such as can be obtained after treatment with restriction enzyrnes.
In initial experiments, we have been unable to detect an agent in the spontaneously transformed Ch-LCL that is capable of transforming human cord blood or leukocytes of EBV seronegative marmosets. This may be due to the restricted host range of this agent. The prevalence of antibody to the agent in the sera of chimpanzees and other non-human primates suggests that the agent is highly infectious. Attempts at demonstrating the biological activity of this EBV-related virus are therefore continuing.
